Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Author:
Affiliation:
1. Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA
2. Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
3. Consultant, Fueerbarg 16a, D-22393 Hamburg, Germany
Publisher
Informa UK Limited
Subject
Drug Discovery
Link
https://www.tandfonline.com/doi/pdf/10.1517/17460441.2013.741580
Reference130 articles.
1. Standards of Medical Care in Diabetes—2012
2. Fatty Liver
3. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
4. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
5. Lessons from Human Studies with Glucagon-Like Peptide-1: Potential of the Gut Hormone for Clinical Use
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28
2. Porous silicon and silica carriers for delivery of peptide therapeutics;Drug Delivery and Translational Research;2024-05-31
3. Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management;Endocrinology and Metabolism;2024-04-30
4. Exendin-4 affects calcium signalling predominantly during activation and activity of beta cell networks in acute mouse pancreas tissue slices;Frontiers in Endocrinology;2024-01-16
5. The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice;Protein Expression and Purification;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3